SCHEMBL3948593

SCHEMBL3948593

Cc1c(Br)cc(C(=O)O)c(C)c1[N+](=O)[O-]

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2D O15399 1/20 0.45
GRIN3B O60391 1/20 0.45
GRIN1 Q05586 1/20 0.45
GRIN2A Q12879 1/20 0.45
GRIN2B Q13224 1/20 0.45
GRIN2C Q14957 1/20 0.45
GRIN3A Q8TCU5 1/20 0.45
TSHR P16473 3/20 0.44
PKM P14618 1/20 0.43
GPR35 Q9HC97 1/20 0.43
ALDH1A1 P00352 3/20 0.41
CYP1A2 P05177 2/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C19 P33261 1/20 0.41
HNF4A P41235 2/20 0.39
MAPT P10636 2/20 0.37
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
TDP1 Q9NUW8 2/20 0.37
KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31188092 0.87 TSHR (0.50) TSHRPKMALDH1A1CYP1A2CYP2D6
SCHEMBL18641452 0.85 TSHR (0.41) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL2259930 0.82 TSHR (0.46) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL13468095 0.82 GRIN2D (0.42) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL13280374 0.81 TSHR (0.42) TSHRPKMGPR35ALDH1A1CYP1A2
SCHEMBL13280377 0.81 TSHR (0.42) TSHRPKMGPR35ALDH1A1CYP1A2
SCHEMBL11756245 0.81 TSHR (0.53) TSHRPKMGPR35ALDH1A1CYP1A2
SCHEMBL29634343 0.81 TSHR (0.53) TSHRPKMGPR35ALDH1A1CYP1A2
SCHEMBL9013992 0.81 TSHR (0.49) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL8068839 0.79 TSHR (0.51) TSHRPKMGPR35ALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3470396-A1 SUBSTITUTED BENZENE COMPOUNDS Epizyme, Inc. (US) 2019-04-17 EP disclosed
CN-104066718-B Substituted benzene compounds EPIZYME股份有限公司 2017-08-29 CN disclosed
EP-3165520-A1 SUBSTITUTED BENZENE COMPOUNDS Epizyme Inc (US) 2017-05-10 EP disclosed
EP-3165520-A1 SUBSTITUTED BENZENE COMPOUNDS Epizyme Inc (US) 2017-05-10 EP disclosed
US-20160332969-A1 SUBSTITUTED BENZENE COMPOUNDS Epizyme, Inc. 2016-11-17 US disclosed
US-9376422-B2 Dihidropyridin-2-one benzamine compounds Epizyme, Inc. (US) 2016-06-28 US disclosed
EP-2697198-B1 SUBSTITUTED BENZENE COMPOUNDS EPIZYME INC (US) 2016-06-08 EP disclosed
EP-2697198-B1 SUBSTITUTED BENZENE COMPOUNDS EPIZYME INC (US) 2016-06-08 EP disclosed
CN-104066718-A Substituted benzene compounds EPIZYME INC 2014-09-24 CN disclosed
US-20140142083-A1 Substituted Benzene Compounds Epizyme, Inc. (US) 2014-05-22 US disclosed
US-20140142083-A1 Substituted Benzene Compounds Epizyme, Inc. (US) 2014-05-22 US disclosed
US-20140142083-A1 Substituted Benzene Compounds Epizyme, Inc. (US) 2014-05-22 US disclosed
EP-2697198-A1 SUBSTITUTED BENZENE COMPOUNDS Epizyme, Inc. (US) 2014-02-19 EP disclosed
WO-2012142513-A1 SUBSTITUTED BENZENE COMPOUNDS Epizyme, Inc. (US) 2012-10-18 WO disclosed
WO-2012142513-A1 SUBSTITUTED BENZENE COMPOUNDS Epizyme, Inc. (US) 2012-10-18 WO disclosed
EP-1940394-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2009-07-08 EP disclosed
US-20080262040-A1 novel indazole carboxamide derivatives for inflammatory and tissue repair disorders like rheumatoid arthritis, asthma, and COPD; kinase inhibitors in particular IKK2; 1,1-dimethylethyl-4-[4-(aminocarbonyl)-6-phenyl-1H-indazol-1-yl]-1-piperidinecarboxylate; intermediates SMITHKLINE BEECHAM CORPORATION 2008-10-23 US disclosed
EP-1940394-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2008-07-09 EP disclosed
WO-2007102883-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2007-09-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262040-A1 novel indazole carboxamide derivatives for inflammatory and tissue repair disorders like rheumatoid arthritis, asthma, and COPD; kinase inhibitors in particular IKK2; 1,1-dimethylethyl-4-[4-(aminocarbonyl)-6-phenyl-1H-indazol-1-yl]-1-piperidinecarboxylate; intermediates IRAK2, NFKBIA, IRAK1 GRIN2D 2529/4885GRIN3B 3357/4885GRIN1 1685/4885
US-20140142083-A1 Substituted Benzene Compounds CYP1B1, TP53, VHL GRIN2D 4812/4885GRIN3B 4539/4885GRIN1 4848/4885
US-20160332969-A1 SUBSTITUTED BENZENE COMPOUNDS CYP1B1, TP53, VHL GRIN2D 4812/4885GRIN3B 4539/4885GRIN1 4848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.